SCYNEXIS Net Income 2011-2026 | SCYX

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income SCYNEXIS

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-8.61 M	-21.3 M	67 M	-62.8 M	-32.9 M	-55.2 M	-53.7 M	-12.5 M	-25.1 M	-30 M	-32.6 M	-4.23 M	-30.5 M	-11.5 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
67 M	-62.8 M	-22.4 M

Quarterly Net Income SCYNEXIS

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-8.59 M	-6.88 M	-5.39 M	-	-2.81 M	-14.5 M	411 K	-	-1.76 M	122 M	-33.9 M	-	-29.6 M	-13.3 M	-5.45 M	-	-605 K	1.66 M	-4.68 M	-	909 K	-6.38 M	-7 M	-	-7.94 M	-8.4 M	-22.9 M	-	351 K	-10.8 M	-4 M	-	-8.4 M	-4.2 M	-4.87 M	-3.45 M	-11.2 M	-8.13 M	-7.18 M	-8.39 M	-8.36 M	-9.5 M	-6.38 M	-	-3.8 M	2.23 M	412 K	-	-3.96 M	-2.7 M	-2.07 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
122 M	-33.9 M	-3.88 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Drug manufacturers industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Aurora Cannabis ACB	-695 M	$ 3.45	0.58 %	$ 86.3 M	Canada
Alimera Sciences ALIM	-20.1 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	-26.5 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-74.8 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	-13 M	-	7.5 %	$ 6.35 M	USA
Canopy Growth Corporation CGC	-598 M	$ 1.02	-	$ 110 M	Canada
Agile Therapeutics AGRX	-14.5 M	-	10.11 %	$ 58.2 M	USA
Cronos Group CRON	-73.1 M	$ 2.54	1.6 %	$ 1.33 B	Canada
Assertio Holdings ASRT	-30.4 M	$ 11.77	1.99 %	$ 836 M	USA
DURECT Corporation DRRX	-27.6 M	-	-	$ 50.1 M	USA
Avadel Pharmaceuticals plc AVDL	-48.8 M	-	-	$ 2.06 B	France
Eagle Pharmaceuticals EGRX	35.6 M	-	-39.89 %	$ 27.7 M	USA
Evolus EOLS	-51.6 M	$ 5.04	0.6 %	$ 325 M	USA
Evoke Pharma EVOK	-7.79 M	-	-	$ 36.6 M	USA
Calliditas Therapeutics AB (publ) CALT	-510 M	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	-115 M	-	2.45 %	$ 38.1 M	Canada
Catalent CTLT	-1.04 B	-	-	$ 11.5 B	USA
Cumberland Pharmaceuticals CPIX	-1.9 M	$ 3.06	0.66 %	$ 43 M	USA
Jupiter Wellness JUPW	-49.4 M	-	-	$ 33.6 M	USA
Athenex ATNX	-103 M	-	-23.39 %	$ 1.76 M	USA
Endo International plc ENDP	-2.45 B	-	-	$ 28.9 M	Irlanda
Harrow Health HROW	-5.14 M	$ 34.91	2.38 %	$ 1.28 B	USA
Emergent BioSolutions EBS	-760 M	$ 8.33	3.22 %	$ 426 M	USA
OrganiGram Holdings OGI	-131 M	$ 1.42	0.71 %	$ 402 M	Canada
China Pharma Holdings CPHI	-4.74 M	$ 0.62	2.94 %	$ 10.8 M	China
Sundial Growers SNDL	-230 M	$ 1.44	-4.64 %	$ 3.37 M	Canada
Organogenesis Holdings ORGO	861 K	$ 2.58	-2.27 %	$ 340 M	USA
Pacira BioSciences PCRX	-99.6 M	$ 22.69	-2.45 %	$ 1.05 B	USA
ProPhase Labs PRPH	18.5 M	-	-	$ 5.07 M	USA
Lannett Company LCI	-232 M	-	1.15 %	$ 7.11 M	USA
Radius Health RDUS	-70.2 M	-	-	$ 1.42 B	USA
Perrigo Company plc PRGO	-1.43 B	$ 9.72	4.4 %	$ 1.35 B	USA
Neoleukin Therapeutics NLTX	13.7 M	-	-	$ 193 M	Canada
Sonoma Pharmaceuticals SNOA	-3.46 M	$ 2.4	-2.24 %	$ 2.98 M	USA
Relmada Therapeutics RLMD	-98.8 M	$ 6.18	4.57 %	$ 186 M	USA
Rockwell Medical RMTI	-8.44 M	$ 0.96	6.61 %	$ 22.4 M	USA
PetIQ PETQ	2.13 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	-35.5 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	-46.1 M	-	-27.8 %	$ 2.56 M	USA
Recro Pharma REPH	-13.3 M	-	-4.76 %	$ 65.3 M	USA
TherapeuticsMD TXMD	-10.3 M	$ 2.17	-	$ 22.7 M	USA
Solid Biosciences SLDB	-125 M	$ 7.48	2.33 %	$ 305 M	USA
Veru VERU	-37.8 M	$ 2.37	-0.84 %	$ 320 M	USA
Tilray TLRY	-1.45 B	$ 6.9	0.15 %	$ 4.26 B	Canada
Viatris VTRS	54.7 M	$ 13.51	-	$ 16.2 B	USA
Tricida TCDA	-177 M	-	-	$ 3.25 M	USA
cbdMD YCBD	-153 K	$ 0.72	1.41 %	$ 3.11 M	USA
Zynerba Pharmaceuticals ZYNE	-35 M	-	-	$ 55.5 M	USA
Zomedica Corp. ZOM	-81.9 M	-	-0.21 %	$ 98 M	USA